An observational study evaluating drug–drug interactions between ledipasvir/sofosbuvir and other medications in children and adolescents with hepatitis C virus
Latest Information Update: 04 Jul 2019
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Amlodipine; Amoxicillin; Aspirin; Azathioprine; Betamethasone; Calcium carbonate; Captopril; Cefepime; Chlorphenamine; Ciclosporin; Colchicine; Colecalciferol; Cyclophosphamide; Deferoxamine; Diclofenac; Fludrocortisone; Folic acid; Furosemide; Hydroxycarbamide; Hydroxychloroquine; Insulin; Iron; Leflunomide; Levetiracetam; Levocarnitine; Mesalazine; Methyldopa; Methylprednisolone; Metronidazole; Montelukast; Mycophenolate mofetil; Nitazoxanide; Ondansetron; Pantoprazole; Paracetamol; Penicillins; Piracetam; Prednisolone; Propranolol; Ranitidine; Sertaconazole; Sodium bicarbonate; Sotalol; Spironolactone; Sulfasalazine; Terbutaline; Ursodeoxycholic acid; Warfarin
- Indications Hepatitis C
- Focus Adverse reactions
Most Recent Events
- 04 Jul 2019 New trial record
- 25 Jun 2019 Results published in the Clinical Drug Investigation